Back to Search Start Over

Activity and Safety of Bortezomib and Rituximab In Relapsed/refractory Indolent Non Follicular and Mantle-cell Non Hodgkin Lymphoma: A Phase Ii Multicenter Study By Intergruppo Italiano Linfomi